RFP: Content Development and Delivery of an Accredited Electronic Continuing Medical Education Course for Health Professionals

Prostate Cancer Canada invites applications from individuals or organizations interested in the development, promotion, and delivery of an accredited electronic Continuing Medical Education (eCME) course targeting health professionals (HPs) to develop advocacy skills to lead change and influence health decision makers at the federal, provincial, and institutional level. While the primary target audience are HPs who work with prostate cancer patients, the course is open to all HPs (e.g. general practitioners, nurse-practitioners, nurses, pharmacists). The provider will propose a cost-effective way to accredit the course with multiple regulating bodies and provide a certificate of completion for health professionals ineligible for accreditation. The eCME course will be a presentation with audio-visual components.  All content will be made available in English and French. The anticipated start date of the course will be September 2019 and the course will be made available for one year after launch.

Key Dates

Issue Date Monday, April 22, 2019
Application Deadline Date Wednesday, May 22, 2019
Anticipated Notification Date Friday, June 7, 2019
Project End Date July 2020

For more information, please see the full RFP here.

Frequently Asked Questions


Q: What is the minimum number of clinicians required on the faculty?
A: For each accrediting body, there should be 2-3 clinicians on the faculty. The provider will propose a cost-effective way to accredit the course with multiple regulating bodies and provide a certificate of completion for health professionals ineligible for accreditation.

Q: Who is the target audience?
A: While the primary target audience are health professionals who work with prostate cancer patients, the course is open to all health professionals (e.g. general practitioners, nurse-practitioners, nurses, pharmacists).

Q: When will the course be made available?
A: The anticipated start date of the course will be September 2019. The timeline may be extended upon consultation, if required.

Q: Should the course content apply to all audiences?
A: Yes.

Q: What is the budget for this RFP?
A: We are open to reviewing different levels of solutions. Please present a quote that matches the objectives of the proposal.

​Q: How will faculty members be chosen for the accredited course?
A: Faculty members will be officially invited to participate in the program by the relevant accrediting organizations. PCC will discuss potential faculty members with the successful vendor who will make the recommendation to the accrediting organization.

Q: The RFP indicates the services must be provided by one organization. Can the vendor work with partners that assist in promotion?
A: PCC will enter into a contract with one organization to provide the physician education course. Any external parties that the successful vendor chooses to consult/work with for this project will be their sole discretion.

Q: Does PCC have a preferred translation provider with whom the successful vendor will partner?
A: No, however PCC does work with a company who has translated program content in the past and will disclose this information to the successful vendor upon request.

Q: Does PCC already have a bank of videos, images, etc. that the successful vendor may be able to tap into?
A: PCC will share any relevant assets that may be helpful for this course. New assets are also expected to enhance course delivery.

Q: Was the RFP formally circulated directly to a group of potential providers, or only posted on your website, or both? 
A: Both.
 
RFP page last updated April 2019

Donate Now!

Go Plaid. Help Dad.


Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.
More

Researchers discover common markers of tumour hypoxia across 19 cancer types

Landmark pan-cancer study analyzes mutation signatures of low oxygen in more than 8,000 tumours
More

Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More


Click here for news archive